Effect of Low-Dose Radiotherapy on the Circulating Levels of Paraoxonase-1-Related Variables and Markers of Inflammation in Patients with COVID-19 Pneumonia

Identificador:  imarina:9267376

Handle: https://hdl.handle.net/20.500.11797/imarina9267376

Autores:  Rodríguez-Tomàs, E; Acosta, JC; Torres-Royo, L; De Febrer, G; Baiges-Gaya, G; Castañé, H; Jiménez, A; Vasco, C; Araguas, P; Gómez, J; Malave, B; Arquez, M; Calderón, D; Piqué, B; Algara, M; Montero, A; Simó, JM; Gabaldó-Barrios, X; Sabater, S; Camps, J; Joven, J; Arenas, M

Resumen:
The aim of our study was to investigate the changes produced by low-dose radiotherapy (LDRT) in the circulating levels of the antioxidant enzyme paraoxonase-1 (PON1) and inflammatory markers in patients with COVID-19 pneumonia treated with LDRT and their interactions with clinical and radiological changes. Data were collected from the IPACOVID prospective clinical trial (NCT04380818). The study included 30 patients treated with a whole-lung dose of 0.5 Gy. Clinical follow-up, as well as PON1-related variables, cytokines, and radiological parameters were analyzed before LDRT, at 24 h, and 1 week after treatment. Twenty-five patients (83.3%) survived 1 week after LDRT. Respiratory function and radiological images improved in survivors. Twenty-four hours after LDRT, PON1 concentration significantly decreased, while transforming growth factor beta 1 (TGF-beta 1) increased with respect to baseline. One week after LDRT, patients had increased PON1 activities and lower PON1 and TGF-beta 1 concentrations compared with 24 h after LDRT, PON1 specific activity increased, lactate dehydrogenase (LDH), and C-reactive protein (CRP) decreased, and CD4+ and CD8+ cells increased after one week. Our results highlight the benefit of LDRT in patients with COVID-19 pneumonia and it might be mediated, at least in part, by an increase in serum PON1 activity at one week and an increase in TGF-beta 1 concentrations at 24 h.